EUVIMEDEUVIMED entdecken
Multizentrische Studie

Standard neoadjuvant immunotherapy in patients with resectable stage III Melanoma – The early Australian experience

Francis Proulx-Rocray, Rebecca Symons, Yang Wang, Samrin Liaqat, Lydia Warburton, Claresta Jiang, Terence Wong, Edward Hsiao, Sydney Ch'ng, Kerwin F Shannon, Michael Rtshiladze, Thomas E Pennington und 19 weitere

European Journal of Cancer · 2026-07 · 243 · 116865

DOI: 10.1016/j.ejca.2026.116865 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2026-07. Verfasst von Francis Proulx-Rocray und 30 weiteren Autor:innen. Beteiligte Einrichtung: Melanoma Institute Australia, Sydney, Australia; Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Canada. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Immunotherapy, Melanoma, Neoadjuvant Therapy. Die Arbeit nennt 37 Literaturangaben. Gefördert von: National Health and Medical Research Council, Melanoma Institute Australia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Neoadjuvant immune checkpoint inhibitor therapy (nICI) improves outcomes in stage III melanoma. Real-world data remain limited, especially in patient subgroups ineligible for trials or undergoing approaches deviating from trial protocols. METHODS Retrospective review of all patients who received nICI outside clinical trials for resectable stage IIIB-D melanoma across 8 Australian institutions. Baseline characteristics, treatment details, radiological and pathological responses, event-free survival (EFS) and recurrence-free survival (RFS) were examined. RESULTS From June 2023 to October 2025, 268 patients received nICI; 173 (65%) had lymph node (LN) metastases only, 65 (24%) had in-transit metastases (ITM) only, and 30 (11%) had both. Anti-PD-1 monotherapy (mono) was used in 198 patients (74%); 70 (26%) received anti-PD-1 + anti-CTLA-4 (combo). Surgery was performed in 227 patients (85%), while 41 (15%) did not proceed to surgery: 25 following clinical complete response (cCR), 14 due to progression, and 2 due to toxicity. Major pathological response (MPR) was achieved in 118 patients (52%). At a median follow-up of 12.1 months, combo was associated with higher 12-month EFS than mono (85.6% vs 75.6%, p < 0.05). Patients with MPR to mono who omitted adjuvant ICI had lower 12-month RFS than those who received it (80.4% vs 100%, p < 0.05); this difference was not observed after MPR to combo. ITM-only patients had similar 12-month EFS to LN-only patients (76.2% vs 81.0%, p = 0.13). No patient managed nonoperatively after cCR recurred. CONCLUSION Neoadjuvant ICI is feasible in real-world practice, including for ITM-only disease. Following MPR to mono, adjuvant ICI confers superior outcomes than omitting it.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsImmunotherapyMelanomaNeoadjuvant TherapySkin NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedAustraliaNeoplasm StagingRetrospective Studies

Stichwörter der Autor:innen

AdjuvantImmune checkpoint inhibitorsImmunotherapyIn-transit metastasesMelanomaNeoadjuvantNonoperative managementReal-world

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Melanoma Institute Australia, Sydney, Australia; Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Canada.
  • Melanoma Institute Australia, Sydney, Australia.
  • Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Fiona Stanley Hospital, Perth, Australia; Hollywood Private Hospital, Perth, Australia.
  • Fiona Stanley Hospital, Perth, Australia; Centre for Precision Health, Edith Cowan University, Joondalup, Australia.
  • Westmead Hospital, Sydney, Australia.

Förderung

  • National Health and Medical Research Council
  • Melanoma Institute Australia

Zitieren

APA

Proulx-Rocray, F., Symons, R., Wang, Y., Liaqat, S., Warburton, L., Jiang, C., Wong, T., Hsiao, E., Ch'ng, S., Shannon, K. F., Rtshiladze, M., Pennington, T. E., Coker, D. J., Carlino, M. S., Spillane, A., Stretch, J., Saw, R. P. M., van Akkooi, A. C. J., Snow, H., …, & Menzies, A. M. (2026). Standard neoadjuvant immunotherapy in patients with resectable stage III Melanoma – The early Australian experience. European Journal of Cancer, 243, 116865. https://doi.org/10.1016/j.ejca.2026.116865

Vancouver

Proulx-Rocray F, Symons R, Wang Y, Liaqat S, Warburton L, Jiang C, et al. Standard neoadjuvant immunotherapy in patients with resectable stage III Melanoma – The early Australian experience. European Journal of Cancer. 2026;243:116865. doi:10.1016/j.ejca.2026.116865

BibTeX
@article{ProulxRocray2026,
  author = {Proulx-Rocray, Francis and Symons, Rebecca and Wang, Yang and Liaqat, Samrin and Warburton, Lydia and Jiang, Claresta and Wong, Terence and Hsiao, Edward and Ch'ng, Sydney and Shannon, Kerwin F and Rtshiladze, Michael and Pennington, Thomas E and Coker, David J and Carlino, Matteo S and Spillane, Andrew and Stretch, Jonathan and Saw, Robyn P M and van Akkooi, Alexander C J and Snow, Hayden and Gyorki, David E and Spain, Lavinia and Jackett, Louise A and Atkinson, Victoria and Roberts-Thomson, Rachel and Dzienis, Marcin and Khattak, Adnan and Sandhu, Shahneen and Rawson, Robert V and Lo, Serigne N and Long, Georgina V and Menzies, Alexander M},
  title = {Standard neoadjuvant immunotherapy in patients with resectable stage III Melanoma – The early Australian experience},
  journal = {European Journal of Cancer},
  year = {2026},
  volume = {243},
  pages = {116865},
  doi = {10.1016/j.ejca.2026.116865}
}
Kostenlos starten →